On May 5, 2019, Hansoh’s Fulaimei (Polyethylene Glycol Loxenatide for Injection) (available in 0.5ml:0.1mg and 0.5ml:0.2mg) received NDA approval from National Medical Products Administration.

Polyethylene Glycol Loxenatide is a GLP-1 receptor agonist. It is a Category 1.1 innovative drug, independently developed by Hansoh based on long-acting drug proprietary technology, for the treatment of type 2 diabetes. As a result of its molecular structure, Polyethylene Glycol Loxenatide only needs one injection per week to achieve a long-term effect.